Final Recommendation Statement: Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions
Agency for Healthcare Research and Quality (AHRQ) sent this bulletin at 10/23/2012 08:00 AM EDT
The U.S. Preventive Services Task Force issued today its final recommendation statement on menopausal hormone therapy for the primary prevention of chronic conditions. To view the recommendation and the evidence on which it is based, please click here. A fact sheet that explains the final recommendation statement in plain language is also available on this Web page. The final recommendation can also be found in the October 23 online issue of Annals of Internal Medicine.
You Are Here: U.S. Preventive Services Task Force > Topic Index > Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions
Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions
This topic page summarizes the U.S. Preventive Services Task Force (USPSTF) recommendations on menopausal hormone therapy for the primary prevention of chronic conditions.
Current Recommendations
Release Date: October 2012- The USPSTF recommends against the use of combined estrogen and progestin for the prevention of chronic conditions in postmenopausal women.
Grade: D Recommendation. - The USPSTF recommends against the use of estrogen for the prevention of chronic conditions in postmenopausal women who have had a hysterectomy.
Grade: D Recommendation.
Supporting Documents
Supporting Document | Related Items |
---|---|
Recommendation Statement (PDF File, 157 KB; PDF Help) | Clinical Summary (PDF File, 57 KB; PDF Help) |
Consumer Fact Sheet (PDF File, 114 KB; PDF Help) | |
Evidence Report (PDF File, 164 KB; PDF Help) | Evidence Synthesis (PDF File, 1 MB; PDF Help) |
Current as of October 2012
Internet Citation:
Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions, Topic Page. October 2012. U.S. Preventive Services Task Force. http://elbiruniblogspotcom.blogspot.com
No hay comentarios:
Publicar un comentario